Noelle Crombie of The Oregonian publicized that the provisional marijuana based drug Epidiolex was found to be remarkably efficient. Made with pure CBD (cannabidiol), it has been found to decrease epileptic seizures associated with a rare form of epilepsy called Dravet syndrome.
The company in charge of producing the product is GW Pharmaceuticals. GW said that Epidiolex achieved the main goal of the trial. The drug has been shown to shrink the uncontrollable convulsive seizures when directly analyzed and contrasted with a placebo in patients that suffer from Dravet syndrome.
The New York Times interviewed the study’s lead investigator, Dr. Orrin Devinsky of the Comprehensive Epilepsy Center at New York University Langone Medical Center, “I’m very proud and happy about this study because it is science — we did things the way they should be done, I would strongly advocate that in the United States we need to do systematic assessments of medical marijuana.”
GW Pharmaceuticals specified that patients taking Epidiolex saw a 39 percent decrease in their recurrent “convulsive seizures” during the study, according to the New York Times.
Newsweek covered the story as well, citing that GW was founded with the overall goal of providing medicinal benefits with the use of medical marijuana without incorporating the effects you get when smoking.
Crombie mentions that writer and editor Fred Vogelstein spoke with The Oregonian/Oregonlive about his family’s experience with Epidiolex. As a result Vogelstein’s teenage son, Sam, saw a prodigious change and reduction in the amount of seizures he suffered from day to day while using the drug.
A quote from Vogelstein, “It’s not a miracle drug in the sense that it only helps half the kids, but those are kids like Sam for whom no other drugs had been previously effective. All the kids in the trials are kids like Sam who have tried every other medicine under the sun unsuccessfully and gotten no relief. If this drug moved that needle it would make it one of the most important epilepsy drugs ever invented”.
The Wall Street Journal noted that GW Pharma is already providing Epidiolex to more than 375 children with many different forms of epilepsy under an extended access program, which allows patients with serious conditions to use drugs that haven’t yet gained regulatory approval.
The drug would actually be the first treatment of its kind targeted at Dravet syndrome, a rare form of childhood epilepsy estimated to affect between one in 16,000 and one in 21,000 people, according to an estimate published in the journal Pediatrics last year.
(Photo Courtesy of www.upi.com)